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Abstract
Purpose
Although locally invasive or recurrent fibromatosis is primarily treated with surgery, radio-
therapy (RT) produces local control for recurrent/unresectable tumors or those with positive
surgical margins. Herein, we describe our updated institutional experience with RT to treat
fibromatosis.
Methods
Forty-seven patients with fibromatosis received RT between 1990 and 2015, and were fol-
lowed for12 months. Eight patients received RT for gross tumors, and 39 received postop-
erative RT after single/multiple prior surgeries. A median dose of 54 Gy was prescribed for
definitive RT; 48.6, 50.4, and 54 Gy were prescribed for R0, R1, and R2 resected tumors,
respectively. Recurrences were classified as in-field, marginal, or out-field. Prognostic fac-
tors were also evaluated.
Results
Seven recurrences were noted, including 2 in-field, 4 marginal, and 1 out-field, after a
median follow-up of 60 months. In-field recurrences occurred in 1 patient who received 40.5
Gy of salvage RT after postoperative recurrence and another who received 45 Gy for R1
resection after multiple prior operations. All marginal failures were due to insufficient clinical
target volume (CTV) margins regardless of dose (3 with 45 Gy and 1 with 54 Gy). On multi-
variate analysis, a CTV margin5 cm and dose >45 Gy were significant predictors of non-
recurrence (p = 0.039 and 0.049, respectively). Subgroup analysis showed that patients
with both an CTV margin5 cm and a dose >45 Gy showed a favorable outcome.
Conclusions
RT is a valuable option for treating aggressive fibromatosis; doses45 Gy and a large field
produce optimal results. For in-field control, a higher dose is more necessary for gross resid-
ual tumors than for totally excised lesions.
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Introduction
Aggressive fibromatosis (i.e., a desmoid tumor) is histologically benign but often shows aggres-
sive features [1–3], as it can infiltrate adjacent tissues and cause local symptoms. The manage-
ment of fibromatosis remains controversial, and the optimal treatment policy is still unclear
[4]. Despite recent clinical guidelines [5–7], the rarity of fibromatosis and its complex behavior
have rendered it difficult to establish universal treatment guidelines.
Surgery was once the primary treatment for aggressive fibromatosis. However, physicians
have tended to avoid such interventions owing to high recurrence rates, possible iatrogenic
morbidity, and a better understanding of a tumor’s natural history. Several predictors of
tumor recurrence have been discovered; these have further stressed the need for adjuvant
treatment in patients deemed to be high-risk [8]. To that end, radiotherapy (RT) has been sug-
gested for patients with positive margins, recurrent lesions, or unresectable tumors. Although
an optimal adjuvant RT protocol has yet to be adopted, many groups have reported long-term
local control rates of 70–93% with a sufficient RT dose to the gross tumor.
There are no guidelines regarding the optimal radiation dose and extent of radiation vol-
ume for treating fibromatosis. Although several retrospective studies showed significantly
more favorable local control rates at higher doses (50–60 Gy) [9–12], the dose-response rela-
tionship in patients with fibromatosis remains unclear. Moreover, since previous studies did
not use unified RT fields, determining the exact dose-response relationship is difficult. In our
previous series [13], we showed that aggressive fibromatosis with microscopic or gross residual
disease could be well controlled with a moderate dose only if the field was adequate. The extent
of coverage has also been shown to depend on several factors such as tumor size, number of
prior recurrences, extent of surgery, and position of the tumor within a path of least resistance
[14]. In previous studies, including ours, a generous surgical margin of 5–10 cm was generally
recommended [11,12,15,16]. We suggested a margin5 cm, regardless of adjacent normal tis-
sue barriers, based on our data on marginal failures [13].
As a follow-up to our recent study, we present herein our updated experience and the long-
term outcomes of additional patients with aggressive fibromatosis who received definitive or
postoperative RT. We also offer new perspectives on RT doses and fields in patients with
fibromatosis.
Materials and methods
Patient selection
We identified 56 patients who were diagnosed with fibromatosis and received their first RT
between January 1990 and December 2015 at Severance Hospital. One patient who could not
complete the whole RT session, 2 who had other secondary malignancies, 3 without follow-up
data, and 3 without sufficient follow-up (<12 months) were excluded. Therefore, 47 patients
were included in this retrospective study. The institutional review board of Yonsei University
approved this study (approval number 4-2017-1064). The patient records/information was
anonymized and de-identified prior to analysis, and informed consent was not obtained from
each participants.
Treatment
The treatment plans at our institution are individualized based on the clinical symptoms; loca-
tion, size, and growth of the tumor; potential for complete resection without significant mor-
bidity; and the patient’s preference. During our study period, planning often involved a
multidisciplinary team of physicians from different departments. Surgical removal was
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primarily considered for fibromatosis when a safe surgical resection was possible. RT was per-
formed in some patients with gross or microscopic residual disease following surgery or for
those with unresectable tumors. RT was also performed in an adjuvant setting after a histologi-
cally complete resection, especially in patients with a recurrent tumor following surgery.
RT was administered using 4–10 MV X-rays, and 2D- or 3D-conformal RT was selected for
most patients. Before 2000, 2D RT was used, whereas 3D RT was primarily employed thereaf-
ter. Considering the treatment site and target conformity, intensity-modulated radiotherapy
was considered in some patients. Fractionation schedules were 5 days/week, with a daily frac-
tion of 1.8 or 2 Gy. If the irradiated area was within the abdomen or the field was too broad, a
daily fraction of 1.5 Gy was also considered. In both definitive and postoperative RT, we
planned to administer a total dose of45 Gy unless an exception was noted. When RT could
be performed adjacent to the bowel, we considered a lower radiation dose. Conversely, if a
gross tumor remained, a higher dose of>45 Gy was prescribed. For RT volumes, the gross
tumor volume was defined as the entire operative bed/gross tumor as measured through imag-
ing studies before and after surgery and was also based on pathological and surgical findings.
The clinical target volume (CTV) was defined as the gross tumor volume plus a generous mar-
gin (>1.5–2 cm) to encompass the same muscle compartment. If other critical organs were
located nearby, we reduced the margin tightly. The planning target volume was defined as the
CTV plus a 0.5–1 cm margin. Our institutional technique was described in detail previously
[13].
Response evaluation
Patients were considered to have achieved local control if there was no evidence of disease dur-
ing follow-up after the first RT. Although there was no standardized evaluation scheme owing
to the disease’s benign nature, local recurrences could be detected by the patients themselves,
by primary care physicians, or at follow-up visits at our institution. Computed tomography
(CT), magnetic resonance imaging, and/or biopsy were used to verify locally recurrent disease
when clinically evident. To correct for limitations resulting from individualized follow-ups, we
analyzed only those with follow-up periods >1 year.
Responses were defined according to the Response Evaluation Criteria in Solid Tumors
(version 1.1), as follows: complete response (CR), partial response (PR), stable disease, and
progressive disease (PD). Recurrent lesions in patients with PD were classified as in-field, mar-
ginal, or out-field after comparing the recurrence volumes and dose-volume histograms of
their first RT. The recurrence volumes were contoured using the diagnostic X-ray/CT/mag-
netic resonance images taken at that time, followed by a manual rigid co-registration with the
RT planning CT using bony landmarks and visible soft tissue structures in the immediate
vicinity of the recurred lesion. The dose-volume histograms of the first RT were regenerated.
Treatment failure was classified as “in-field” if95% of the recurrence volume occurred
within the volume receiving95% of the prescribed radiation dose, and as “marginal” if the
recurrence volume border crossed the 95% isodose and<95% of the relapse volume was
located inside the volume receiving95% of the radiation dose. The failure was classified as
“out-field” if it was completely outside the 95% isodose of the target volume.
Statistical analysis
Progression-free survival (PFS) was measured from the first day of RT to the date of recur-
rence/progression or the last follow-up date for patients who did not experience such events.
Overall survival (OS) was estimated from the first day of RT to the date of last follow-up or
death from any cause. PFS and OS rates were calculated using the Kaplan-Meier method.
Radiotherapy for aggressive fibromatosis
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Prognostic impacts of clinical factors were analyzed using the log-rank test (categorical vari-
ables) or logistic regression analysis (continuous variables). To compare the differences in out-
comes according to RT dose, the patients were divided into 2 groups (high-dose vs. low-dose)
using the median value as a cutoff. To investigate difference according to the RT margin (i.e.,
the CTV margin), the patients were divided into 2 groups (<5 cm vs.5 cm margins) as
described previously [13]. Differences in characteristics between the 2 groups were compared
using the chi-squared test. All analyses were performed with SPSS version 23.0 (IBM Inc.,
Armonk, NY, USA) and R version 3.4.0. (R Foundation for Statistical Computing, Vienna,
Austria). A p-value of<0.05 was considered statistically significant.
Results
Patient characteristics
The median age of the 47 patients was 28 (range, 4–66) years; the male-to-female ratio was
1:2.5. Patient and treatment characteristics are shown in Table 1. The lower extremities were
the most common tumor locations (26%). At the time of treatment, the median tumor size
was 7.0 (range, 2.2–26.0) cm.
Eight patients received definitive RT for gross tumors as a single (n = 2) or salvage treat-
ment (n = 6), while the remaining 39 received postoperative RT after single (n = 14) or multi-
ple prior surgeries (n = 25). Among these 39 patients, 5 received RT after R0 resection, 21 after
R1 resection, and 13 after R2 resection. Chemotherapy before RT was performed in 2 patients.
After showing no response, chemotherapy was discontinued and RT was performed with or
without surgical resection. The treatment flowchart is shown in Fig 1.
A median dose of 54.0 (range, 40.5–54.0) Gy was prescribed for definitive RT, and 50.4
(range, 39.6–64.8) Gy was prescribed for postoperative RT. Thirteen patients received 45 Gy
while 5 received <45 Gy. Twenty-nine patients received >45 Gy, of whom 19 received54
Table 1. Patients and treatment characteristics.
Patient characteristics No. % Treatment characteristics No. %
Age (year) Median 28 Surgery Yes 39 83
(4–66) No 8 17
Sex Male 13 28 RM_Status R0 5 83
Female 34 72 R1 21 13
Location Neck 9 19 R2 13 33
Axilla 2 4 Chemotherapy Yes 2 4
Thorax 9 19 No 45 96
Abdomen 2 4 RT modality 2D 25 53
Pelvis 4 9 3D 21 45
Upper extremity 6 13 IMRT 1 2
Lower extremity 12 26 RT duration (days) Median 40
Shoulder 3 6
Tumor Size (cm) Median 7.0 RT total dose (Gy) Median 47.0
(2.2–26.0) (39.6–64.8)
<7cm 22 47 RT fractional dose (Gy) Median 1.8
7cm 25 53 (1.5–2.0)
 Chemotherapy before RT was performed in two patients, and the regimens were Xeloda in one patient and prednimustine, adriamycin, vincristine (VAP) in one
patient.
Abbreviations: RM, resection margin; RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
https://doi.org/10.1371/journal.pone.0198134.t001
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Gy. One patient received <40 Gy owing to a very young age (4 years) and the tumor’s location
in the right infratemporal fossa. Median doses of 54, 50.4, and 48.6 Gy were administered for
R2 (n = 13), R1 (n = 20), and R0 (n = 5) resected tumors, respectively. Intensity-modulated
radiotherapy was administered to 1 patient who received 50 Gy of definitive RT for a large
mass of approximately 8 cm on the left shoulder.
Treatment response and prognostic factors
The median follow-up duration was 59 (range, 12–266) months. Two patients who received
definitive RT as the initial treatment showed CR and no recurrence until the last follow-up
(Fig 1). Meanwhile, of 6 patients who received salvage RT, 1 showed CR, 3 showed PR, 1
showed stable disease, and 1 showed in-field PD. Among patients with postoperative RT, CR
and PR rates of 82% and 3%, respectively, were noted. One patient died of disease-related
causes 150 months after RT. The 5-year PFS and OS rates were 87% and 100%, respectively.
The outcomes of the 7 patients with PD are shown in Table 2. All patients underwent postop-
erative RT after repeat surgeries for repetitive recurrences, except for 1 who received salvage
RT for gross recurrence after 2 prior surgeries. All received 40.5 or 45 Gy, except for 1 who
received 54 Gy for an R2 resected lower extremity tumor and experienced marginal failure due
to an insufficient CTV margin. In patients without recurrence, a median dose of 50.4 Gy for
R0 or R1 resected tumors and 54 Gy for R2 resected tumors were prescribed.
On univariate analysis, primary tumor location and RT dose were significantly associated
with PFS (p = 0.027 and 0.035, respectively). Recurrence rates were higher in the abdomen and
Fig 1. Treatment flowchart of 47 patients with fibromatosis. RT, radiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
https://doi.org/10.1371/journal.pone.0198134.g001
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lower extremities. For postoperative RT, the 5-year PFS rates were not significantly influenced
by resection margins. However, a CTV margin of5 cm and an RT dose of>45 Gy were asso-
ciated with significantly lower recurrence rates (p = 0.039 and 0.049, respectively), suggesting
that both were clinically important factors for recurrences of any type (S1 Table).
Failure patterns and impact of CTV margin and dose. Although the RT dose was signif-
icantly associated with prognosis (hazard ratio, 0.998; 95% confidence interval, 0.996–1.000;
p = 0.038) according to logistic regression (S1 Fig), the importance of the RT field was further
emphasized when analyzing the specific failure pattern. To further investigate the differences
in recurrence patterns as a function of CTV margin and dose, we categorized the patients into
4 groups as follows (Fig 2): Group 1 (margin5 cm, dose >45 Gy), n = 18; Group 2 (margin
5 cm, dose45 Gy), n = 11; Group 3 (margin <5 cm, dose>45 Gy), n = 11; and Group 4
(margin <5 cm, dose45 Gy) n = 7. The numbers of recurrences in these groups were 0, 3, 1,
and 3, respectively (Fig 2), while the 5-year PFS rates were 100%, 75%, 100%, and 54%, respec-
tively (Fig 3). No recurrences occurred in group 1; however, marginal recurrence rates
increased in group 3 (4 patients; margin, <5 cm). In-field recurrences were noted in group 2
(4 patients; RT dose,45 Gy). The in-field was well-controlled at a high RT dose of45 Gy in
most patients (Fig 4); only marginal failures due to insufficient CTV margins occurred regard-
less of dose sufficiency.
No in-field failure occurred among patients who received>45 Gy (Table 2). Only 2 patients
who received 40.5 Gy for gross recurrence (because of tumor multiplicity and tumor location
close to the small bowel) and 45 Gy for an R1-resected tumor after repetitive recurrences expe-
rienced in-field recurrences. Only 1 out-field failure event occurred in a patient who received a
large field of 45 Gy for an R2-resected tumor of the left calf; the recurrence occurred at the left
foot after 51 months. Her disease was well controlled after 118 months following 50.4 Gy of
salvage RT.
Marginal failures occurred in 4 patients, and were due to insufficient (<5 cm) CTV margins
regardless of the RT dose. Two patients (Nos. 2 and 6) underwent postoperative RT for lower
extremity tumors; however, relapse occurred at the upper area of the<5 cm CTV margins.
The superior margin of the field in each patient extended to approximately 3 and 4 cm from
the superior end of the CTV, respectively; CR was achieved after the first RT. The recurrent
Table 2. Detail of seven patients who underwent recurrences.
No. Age
(yr)
Sex Tumor
location
Tumor size
(cm)
RT aim No. of prior
surgeries
RM
status
RT dose
(cGy)
CTV
margin
Group Recurrence
type
PFS
(mo)
Current
status
1 37 F Abdominal
wall
3.5 Salvage 2 4050 <5cm 4 Infield 16 AWD
2 17 F Lower
extremity
10.0 Postoperative 2 R2 5400 <5cm 3 Marginal 63 NED
3 12 F Upper
extremity
9.0 Postoperative 2 R0 4500 5cm 2 Marginal 80 NED
4 30 F Shoulder 18.0 Postoperative 2 R0 4500 <5cm 4 Marginal 8 DOD
5 21 F Lower
extremity
4.0 Postoperative 1 R2 4500 5cm 2 Outfield 51 AWD
6 15 F Lower
extremity
19.0 Postoperative 2 R1 4500 <5cm 4 Marginal 29 NED
7 8 M Lower
extremity
6.6 Postoperative 2 R1 4500 5cm 2 Infield 20 NED
Abbreviations: RT, radiotherapy; RM, resection margin; CTV, clinical target volume; PFS, progression-free survival; AWD, alive with disease; NED, no evidence of
disease; DOD, died of disease.
https://doi.org/10.1371/journal.pone.0198134.t002
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tumors were located at the superior margin of the initial radiation field after 63 and 29 months
in these patients, respectively. Patient No. 2 had a well-controlled status after surgery and 45
Gy of repeat RT. Patient No. 6 also underwent surgery and 45 Gy of repeat RT; however,
another recurrence in the second RT field was noted, which was well-controlled as of the last
follow-up. Another patient (No. 4) received postoperative RT in the inferior portion of the left
trapezius muscle after prior surgeries, and experienced recurrence at the medial margin of the
RT field, along with the cervical and thoracic vertebrae, 9 months later. The remaining patient
(No. 3) received 45 Gy after prior surgeries of the left humerus. The RT margin was >5 cm in
the proximal and distal directions. However, considering a skin reaction near the axilla, we
could not provide a margin of up to 5 cm diagonally, and recurrence occurred in this area
after 80 months.
Discussion
Our previous study [13] analyzed the treatment outcome of 24 patients who received RT
between 1990 and 1998, and emphasized the importance of a wide RT field. The current study
subsequently analyzed 47 patients who received RT during a longer period (1990–2015). Anal-
ysis of the patterns of failure revealed that a sufficient CTV margin remains critical. Moreover,
Fig 2. Patterns of failure among patients categorized into 4 groups according to radiotherapy dose and clinical target volume (CTV) margin. CR, complete
response.
https://doi.org/10.1371/journal.pone.0198134.g002
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we pointed out additional novel aspects related to the RT dose. In this updated analysis, a large
radiation volume was deemed to be required regardless of the adjacent normal tissues. More-
over, a higher dose of 45 Gy may be required for gross residual tumors. At our institution, we
prescribed a median dose of 54 Gy for definitive or postoperative RT for R2 resected tumors
and 50.4 Gy for R1 resected tumors. With these doses, all but 2 of the 47 patients showed good
in-field control rates, confirming that these doses were appropriate for such control.
RT can be an effective treatment option for aggressive fibromatosis and can be considered
for both resected tumors with local recurrences and unresectable tumors as the sole treatment.
Historically, RT was only used in cases of unresectable fibromatosis or in patients who
declined surgery. More recently, RT has also been adopted as a primary treatment option in
Fig 3. Progression-free survival among patients categorized into 4 groups according to radiotherapy dose and clinical target volume (CTV) margin.
https://doi.org/10.1371/journal.pone.0198134.g003
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patients who experience progression after surgery. Several studies reported good long-term
local control rates of 70–93% with RT [11,14,17–19]. Meanwhile, the evidence for adjuvant RT
is insufficient. Nuyttens et al. [15] demonstrated that RT following surgery improved local
control regardless of whether negative margins (94% vs. 72% with and without RT, respec-
tively) or positive margins (75% vs. 41% with and without RT, respectively) were noted. How-
ever, conflicting studies [12,20–22] failed to show any benefit for adjuvant RT, leading to
difficulty in establishing definitive guidelines. Most domestic institutions, including ours, lack
a consensus for RT indications in fibromatosis, but RT is generally considered in patients with
unresectable tumors, those who are likely to develop residual tumors after surgery, or those
with a high local failure risk due to frequent recurrences [23,24]. Furthermore, a 100% in-field
control rate in patients receiving definitive RT in this study, except for only 1 patient receiving
40.5 Gy, represents a high radiosensitivity for fibromatosis. Thus, future studies to widen RT
indications are warranted.
Reliable predictors of an individual tumor’s natural history have been investigated by sev-
eral groups. Young age, female sex, large tumor size, and tumors at the extremities [25] were
independent negative predictors of recurrence-free survival after surgery. In particular, R2
Fig 4. Scatter plots showing distributions according to radiotherapy dose and clinical target volume (CTV) margin. Stars represent patients
with recurrence. The left large star represents 2 patients (at the same dose and field) together, and the right large star represents 3 patients
together. RT, radiotherapy.
https://doi.org/10.1371/journal.pone.0198134.g004
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resections of aggressive fibromatosis were strongly linked to postoperative recurrence [25,26].
However, conflicting results have also been reported [17,27], and a risk of local recurrence
exists even after obtaining negative microscopic margins. However, we found no significant
difference in prognosis according to resection margin status; only RT dose and field margin
were significant prognostic factors. This difference may be due to the small sample size and/or
the study’s retrospective nature, although RT itself can be a very strong prognostic factor. As
in-field local recurrence is basically well controlled by RT, an appropriate RT field and dose
are crucial. The PFS rate of 100% in group 1 of our current study (i.e., patients with a CTV
margin5 cm and dose >45 Gy) was observed (Fig 3); thus, the role of proper RT administra-
tion for any recurrences would be even more pronounced.
Although there were slight differences in the classifications of failure patterns, 82% of local
failures in patients in a recent Finnish study [28] and 30% of local failures in American patients
as reviewed by Nuytten et al. [15] were reported as marginal failures; therefore, adopting a suf-
ficient RT margin is critical [14]. Despite a lack of consensus around an adequate RT margin, a
wide safety margin of 5–10 cm has recently been recommended for fibromatosis [11,12,15,16].
The RT margin does not have to extend beyond the natural barriers of spread (i.e., fascial
planes and bones); however, we strongly recommend a wide RT field coverage regardless of
the adjacent normal tissue barriers. This updated study also strengthens our claim by reporting
2 more marginal failures for the same reason; 1 patient even died owing to an inadequate
margin.
RT doses of 50–56 Gy have been suggested for fibromatosis [9,10], and even doses of60
Gy were proposed for definitive RT. The MDACC study [29] demonstrated improved local
control at>50 Gy for gross disease, but no improved outcome at>56 Gy. In a long-term fol-
low-up study [12], a higher dose was not necessary in either the definitive or adjuvant settings,
as radiation-related complications were significantly greater (>17%) when >56 Gy was
administered. Moreover, Goy et al. [14] demonstrated better local control at>49.6 Gy, while
Nuyttens et al. [15] found significantly improved in-field control at50 Gy for gross tumors.
In the multicenter phase II EORTC trial [30], investigators prescribed 56 Gy for inoperable
tumors and reported a local control rate of 81.5%. However, in some studies, CR was achieved
with a low dose of 35 Gy, while recurrences were detected despite doses>60 Gy [15]. Thus,
the optimal dose remains uncertain, although a higher dose is still required for gross tumors.
Our institution’s practice is to prescribe 45–50 Gy for fibromatosis, which is lower than in pre-
vious studies, based on our findings of locally well-controlled tumors with lower RT doses. No
recurrences occurred with medians of 48 and 45 Gy for gross measurable tumors and micro-
scopic tumors, respectively, in patients with an adequate RT field, and our updated results re-
confirmed these findings. Generally, in-field failure is unlikely if45 Gy is administered; only
the RT field is of concern.
Although RT is effective in treating extra-mesenteric fibromatosis, more data for dose-
response and long-term outcomes are needed. Ballo et al. [11,29] insisted that there was no
dose-response relationship for patients treated with postoperative RT. Conversely, a study in
Finland [28] recently demonstrated a significant dose-response relationship using definitive
and postoperative RT. Our study also showed a significant dose-response relationship in all
patients. However, recurrences of all types, and not necessarily in-field failures alone, were
considered in these studies. Further validation is required by specifically analyzing in-field
recurrences in larger patient cohorts.
Our study had several limitations. First, despite the long-term study period (approximately
25 years), we could not include many patients due to the low referral rate for RT combined
with the rarity of fibromatosis. Second, there were differences between past and present patho-
logical diagnostic criteria. Since 2005, beta-catenin staining has been essential for diagnosing
Radiotherapy for aggressive fibromatosis
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fibromatosis, as it is a differentiating factor from other fibroblastic tumors [31,32]. Therefore,
some unresponsive tumors previously diagnosed as fibromatosis might have been low-grade
sarcomas that required more aggressive RT. Nevertheless, our study is meaningful given the
difficulty of performing prospective studies on fibromatosis; there are only a few studies that
demonstrate long-term outcomes with a large number of patients from a single institution.
In conclusion, RT for aggressive fibromatosis is a valuable option for achieving favorable
long-term in-field control. Even gross residual fibromatosis can be well-controlled with a suffi-
cient dose. However, establishing a wide radiation field considering all initial tumor extents is
necessary, especially for tumors with repeated recurrences. Higher doses (50–54 Gy) should be
considered for residual fibromatosis after surgery than for completely excised tumors.
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